Effects of Marijuana on Neuropathic Pain and Spasticity in Spinal Cord Injury Patients

Status

Enrolling by invitation

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06190470

Enrollment

Registered

2024-01-05

Start date

2024-01-02

Completion date

2024-06-30

Last updated

2024-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury

Keywords

Cannabis, Marijuana, Spinal cord injury, Pain, Spasticity

Brief summary

The goal of this clinical trial is to compare effects of marijuana or cannabis on neuropathic pain and spasticity in spinal cord injury patients. The main question is: Does the cannabis product from KhonKaen University reduce neuropathic pain and spasticity in spinal cord injury patients? The research design is a crossover study. The participants will be randomly into 2 groups: group 1 and group 2. The participants received either cannabis or placebo for 2 weeks. After completing treatment, participants were swapped to the other group for 2 weeks, a wash-out period is 2 weeks. The outcome measurements are pain and spasticity.

Interventions

DRUGPlacebo

Placebo is similar to Cannabis product but do not contain THC.

DRUGCannabis

Cannabis product is from the extraction of the powdered, dried and mature pistillate inflorescences of Cannabis sativa L. containing THC 30mg/ml.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

25 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Spinal cord injury more than 6 months * Neuropathic pain * Pain score \> 3 * Do not response to standard medical treatment * Given inform consent

Exclusion criteria

* Allergy to cannabis * Unstable cardiovascular and pulmonary diseases * Chronic kidney and liver diseases * Psychological disease * Pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Pain score	2 weeks	Visual analog scale

Secondary

Measure	Time frame	Description
Spasticity	2 weeks	Modified Asworth Score
Activities of daily living	2 weeks	to assess functional outcome
Quality of life score	2 weeks	WHO Bref Quality of life questionnaire
H-reflex	2 weeks	Electrodiagnosis

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026